Filing Details
- Accession Number:
- 0001399529-21-000146
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-08-10 20:06:31
- Reporting Period:
- 2021-08-10
- Accepted Time:
- 2021-08-10 20:06:31
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1399529 | Dicerna Pharmaceuticals Inc | DRNA | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1259856 | Douglas Fambrough | C/O Dicerna Pharmaceuticals, Inc. 75 Hayden Avenue Lexington MA 02421 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-08-10 | 5,000 | $22.10 | 43,164 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Footnotes
- The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $22.035 to $22.11, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
- Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).
Billionaire Hedge Funds
